Salvado Maria, Vargas Victor, Vidal Marta, Simon-Talero Macarena, Camacho Jessica, Gamez Josep
Maria Salvado, Josep Gamez, ALS Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain.
World J Gastroenterol. 2015 Sep 28;21(36):10475-9. doi: 10.3748/wjg.v21.i36.10475.
We report a case of acute severe hepatitis resulting from masitinib in a young amyotrophic lateral sclerosis patient. Hepatotoxicity induced by masitinib, a tyrosine kinase inhibitor, is usually transient with mild elevation of transaminases, although acute hepatitis has been not reported to date. The hepatitis was resolved after masitinib was discontinued and a combination of prednisone and azathioprine was started. The transaminases returned to baseline normal values five months later. This is the first case in the hepatitis literature associated with masitinib. The autoimmune role of this drug-induced liver injury is discussed. Physicians should be aware of this potential complication.
我们报告了一例年轻的肌萎缩侧索硬化症患者因服用马西替尼导致急性重症肝炎的病例。马西替尼是一种酪氨酸激酶抑制剂，其引起的肝毒性通常是短暂的，转氨酶轻度升高，不过迄今为止尚未有急性肝炎的报道。停用马西替尼并开始使用泼尼松和硫唑嘌呤联合治疗后，肝炎得到缓解。五个月后转氨酶恢复到基线正常水平。这是肝病文献中与马西替尼相关的首例病例。本文讨论了这种药物性肝损伤的自身免疫作用。医生应意识到这一潜在并发症。
